Group items tagged

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications.

Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012, comprising Aventis Taxotere (docetaxel), Bristol-Myers Squibbs Paraplatin (carboplatin) and Eli Lillys Gemzar (gemcitabine). The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced lung cancer. However, despite their contributions, science has reached a therapeutic plateau.

Prospective partners with the most attractive projects are expected to enhance and expand business potential and scope for uterine cancer therapy globally. Marketers are developing and designing in-licensing and out-licensing strategies based on the identification of emerging players with potentially strong product portfolio. They are also designing effective counter-strategies to gain competitive advantage.

Analytical tools to analyses antibodies and peptides in oncology lead to analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in the antibody and peptide cancer drug competitive landscape. A progress analysis on current and emerging drugs for cancer antibodies in oncology lays down a comprehensive framework for further analysis of the field.

The tool on apoptosis in oncology also assists in analyzing the vast amount of strategic possibilities that have emerged in apoptotic drug development for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future.

A progress analysis on current and emerging drugs on the peptide drug development the reveals promising investment opportunities. Popular products included in the package are Cancer Peptides: From First-in-Class to Best-in-Class; and Peptides in Oncology Drug Pipeline Update 2013.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.